A

AbbVie

Global biopharmaceutical company developing medicines

Head of Representative Office

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's
Minsk, Minsk Region, Belarus
Hybrid
Business & Strategy

About the job

Requirements
  • A university degree in business, economics, medicine, pharmacy, or another relevant discipline is required; advanced business education is an advantage.
  • Significant leadership experience in the pharmaceutical, healthcare, or another highly regulated industry.
  • Demonstrated experience leading a business, country operation, business unit, or substantial cross-functional organization.
  • Strong understanding of commercial strategy, portfolio management, financial planning, and performance management.
  • Experience working with market access, regulatory, medical, legal, compliance, and supply chain functions.
  • Proven ability to lead through a matrix organization and influence stakeholders without relying only on formal authority.
  • Fluent Russian and professional working proficiency in English.
  • Enterprise leadership, strategic and systems thinking, business and financial acumen, ethical judgment, cross-functional integration, external stakeholder management, risk-based decision-making, executive communication, people leadership, resilience, and adaptability.
Responsibilities
  • Provide overall country leadership and translate regional and global priorities into an integrated Belarus strategy and annual operating plan.
  • Establish country priorities across the portfolio, balancing short-term business delivery with long-term portfolio development and organizational sustainability.
  • Identify changes in the external environment and assess their potential impact on the company, its portfolio, and patients’ access to medicines.
  • Integrate commercial, medical, market access, regulatory, finance, legal, compliance, supply chain, public affairs, and other relevant activities around the country agenda.
  • Ensure timely escalation of material business, operational, legal, compliance, or reputational risks.
  • Assume accountability for overall Belarus business performance within the scope and decision rights assigned to the role.
  • Lead the development and execution of business plans, forecasts, and resource allocation decisions.
  • Monitor sales performance, market dynamics, portfolio contribution, operating expenses, and relevant financial indicators.
  • Manage budgets within approved targets and communicate key business assumptions, risks, and opportunities transparently.
  • Drive disciplined execution that balances business delivery, compliance requirements, and long-term organizational interests.
  • Oversee distributor and partner performance, where applicable, and ensure proper governance of commercial relationships.
  • Lead Belarus portfolio strategy, including brand priorities, launch readiness, and lifecycle management for relevant products.
  • Ensure commercial plans are based on an understanding of patient needs, healthcare system priorities, customer insights, competitive dynamics, and access conditions.
  • Coordinate commercial strategy with medical priorities, regulatory pathways, market access objectives, supply requirements, and external engagement.
  • Build sustainable relationships with customers, institutions, and business partners in accordance with company policies and applicable requirements.
  • Lead country input into market access priorities by maintaining a clear view of Belarus funding mechanisms, procurement processes, access pathways, and relevant policy developments.
  • Represent the company in relevant external interactions within the formally delegated scope of authority.
  • Support constructive, transparent, and compliant engagement with healthcare institutions, industry associations, government stakeholders, and other relevant organizations.
  • Protect and strengthen the company’s reputation as a responsible and trusted healthcare partner.
  • Ensure that the Representative Office operates in accordance with applicable legislation, corporate requirements, and the authority granted to the position.
  • Maintain effective local governance and ensure appropriate financial, legal, regulatory, employment, operational, and compliance controls are in place.
  • Promote a strong culture of integrity, ethical decision-making, and personal accountability.
  • Partner with Legal, OEC/Compliance, Finance, HR, Regulatory, and other supporting functions to identify and manage country-level risks.
  • Ensure that material decisions and activities follow required review, approval, and documentation processes.
  • Lead country planning forums and align functional priorities around a single Belarus agenda.
  • Clarify ownership, decision rights, and expected outcomes across local and cluster-based teams.
  • Ensure effective collaboration between employees based in Belarus and functions supporting Belarus from other locations.
  • Ensure timely resolution of cross-functional issues and barriers to execution.
  • Ensure that country insights and requirements are appropriately represented in regional planning and decision-making.
  • Lead, engage, and develop the Belarus organization by building an accountable team, aligning individual objectives with country priorities, and strengthening capabilities for current operations and the future portfolio.
  • Support talent development, succession planning, and retention of critical capabilities.
  • Foster an environment where employees can raise concerns, challenge decisions constructively, and act consistently with company values.
  • Maintain oversight of key operational dependencies, business continuity plans, and country-level risks affecting the Belarus business, including supply continuity, third parties, financial exposure, and corporate reputation.
  • Ensure that local issues requiring regional or global decisions are escalated with a clear assessment, recommended action, and potential business impact.
Desired Qualifications
  • Experience managing external partners, distributors, or complex institutional customers is an advantage.
  • Sound understanding of the Belarus business and healthcare environment is strongly preferred.

About the company

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Oct 22nd, 2026
Abbott stock: $247,767 in shares yields $500 a month in dividends ahead of Q3 earnings

Abbott Laboratories will report third-quarter earnings before the market opens on Wednesday, October 21. Analysts expect earnings of $1.41 per share, up from $1.30 a year earlier, and revenue of $12.99 billion, against $11.37 billion last year. On October 16, TD Cowen analyst Joshua Jennings reiterated a Buy rating and a $135 price target. Abbott pays a quarterly dividend of 63 cents per share ($2.52 a year), a yield of 2.42%. To earn $500 a month ($6,000 a year) from dividends alone, an investor would need about 2,381 shares, or roughly $247,767.

Yahoo Finance
Oct 21st, 2026
Retirees swap Social Security for 5 dividend stocks yielding up to 6.64%

Retirees looking for income beyond Social Security are turning to dividend stocks. The 2027 cost-of-living adjustment is tracking toward 3.3%, and five companies from different industries were screened for dividend safety first, then yield. Verizon yields 6.64% and Altria 6.17%. Verizon's free cash flow guidance of $21.94 billion to $22.14 billion covers its roughly $11.76 billion annual dividend. Altria's payout is about 79% of the low end of its 2026 earnings guidance. Realty Income pays monthly at a 5.99% yield and has raised its dividend 115 consecutive quarters. Enbridge yields 5.95%. AbbVie yields 2.48%, but its quarterly dividend has grown from $0.40 in 2013 to $1.73 in 2026. Risks include satellite competition for Verizon, falling cigarette volumes for Altria, and currency swings for Enbridge.

Yahoo Finance
Oct 19th, 2026
Merck and AbbVie shares jump 39% and 24% in 2026 as dividend picks for a decade

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

Yahoo Finance
Oct 19th, 2026
Buffett warns of a "gambling mood" in markets; Vertex, Eli Lilly and AbbVie built to weather a drop

Warren Buffett, now Berkshire Hathaway's chairman emeritus, gave his bluntest warning yet at the May shareholder meeting. "We've never had people in a more gambling mood than now," he told CNBC, pointing to individuals rushing into short-term options and betting on markets. He said this behaviour is risky for those taking part and may threaten the market, possibly leading to a drop. The article suggests drugmakers as defensive picks, since patients need treatments in any economy. Vertex Pharmaceuticals leads in cystic fibrosis treatment. Eli Lilly's tirzepatide drugs, Mounjaro and Zepbound, earned more than $14 billion of its $23 billion quarterly revenue. AbbVie's Rinvoq and Skyrizi each grew 24%, and it has raised its dividend for more than 50 consecutive years.

Yahoo Finance
Oct 18th, 2026
Ken Griffin's Citadel boosts AbbVie stake 546% in Q2 as defensive dividend play

Citadel founder and chief executive officer Ken Griffin made healthcare his biggest bet in the second quarter. He bought 2.7 million AbbVie shares, a 546% increase from the previous quarter, and added 6.7 million shares of Abbott Laboratories, up 349%. He also raised his Eli Lilly stake by 291%, the third-biggest individual equity add. The moves suggest a defensive stance. Healthcare stocks tend to hold up in downturns, and both AbbVie and Abbott are Dividend Kings, having raised dividends for 54 straight years. AbbVie yields 2.65% and trades at 16 times forward earnings. In the second quarter, its adjusted earnings rose 23% and net revenue rose 10%. Some 75% of analysts covering the stock rate it a buy.